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DNA damage detected with γH2AX induced by
anticancer agents
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Objectives: Differences in the incidences and types of DNA damage induced by antitumor agents for clear cell
carcinoma (CCC) were determined in 2 ovarian CCC cell lines using γH2AX.
Material and methods: The antitumor activity of anticancer agents, CDDP, CBDCA, PTX and SN-38, was examined
using ovarian clear cell carcinoma cultured cell lines (OVISE and RMG-I). After culture, each cell line was treated with
each anticancer agent, the cells were collected, fixed, and then reacted with the anti-γH2AX antibody. γH2AX and
nuclear DNA were then simultaneously detected by flow cytometry using FITC and propidium iodide, respectively,
to determine γH2AX in each cell cycle phase.
Results: After administration of CDDP, DNA damage was frequent in S-phase cells, while cell-cycle arrest occurred
in the G1 and G2/M phases and γH2AX did not increase in CDDP-resistant cells. Sensitivities to CDDP and CBDCA
differed between the two cell lines. The antitumor effect of PTX is induced by G2/M arrest, and combination
treatment with CBDCA, inducing DNA damage in G2/M-phase cells, might be effective.
Conclusions: This is the first study in Japan to evaluate the antitumor activity of anticancer agents by focusing on
the relationship between the cell cycle and DNA damage using γH2AX as an indicator. The immunocytochemical
method used in this study detects γH2AX, which indicates DNA damage even at very low concentrations and with
high sensitivity. Therefore, a promising method of easily and rapidly identifying agents potentially effective against
CCC.
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Clear cell adenocarcinoma (CCC), a subtype of epithelial
ovarian cancer, is less sensitive to chemotherapy and is
thus classified as a refractory ovarian cancer [1]. It has
been shown that a combination of carboplatin (CBDCA)
and paclitaxel (PTX ), a standard therapy for ovarian can-
cer [2,3], is effective against serous adenocarcinoma and
endometrioid adenocarcinoma, with a response rate of ap-
proximately 75%, while CCC has lower response rates* Correspondence: tshoji@iwate-med.ac.jp
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reproduction in any medium, provided the orranging from 18% to 50% [4]. The incidence of CCC has
been increasing and is now 25% in Japan, while that in
Europe is 5-6%. As yet, no treatment for this histological
subtype of ovarian cancer has been established. Histopath-
ology remains the gold standard for classifying epithelial
ovarian cancer subgroups; however, there is emerging
evidence indicating different genetic and molecular pro-
files. Consequently, there is no international consensus
regarding the necessity of establishing treatment strategies
based on histological subtypes. In fact, global clinical trials
of CCC and mucinous adenocarcinoma have already
begun. Although which cytotoxic agents have true efficacy
against CCC remains unknown, small trials in Japan and
basic studies have suggested the efficacy of irinotecanLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical biological characteristics of the cell line
Cell
Line




CCC CAP× 6 courses 60 hours
RMG- 1 Ascites CCC No 60 hours
CCC; clear cell carcinoma
CAP; cyclophosphamide, doxorubicin, cisplatin
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Group (JGOG) started an international randomized con-
trolled trial (RCT) of cisplatin (CDDP)/CPT-11 therapy
with a control arm of CBDCA/TXL (TC) therapy
(JGOG3017/GCIG); patient accrual is ongoing and ap-
proximately 560 patients had been enrolled in the trial as
of July 2010. In addition, an ongoing translational study,
as part of the JGOG3017/GCIG trial, also aims to establish
an updated treatment strategy.
Nucleosomes, units of chromatin, consist of core his-
tones wrapped in 146 bp of DNA and linker DNA. Core
histones are octamers designated H2A, H2B, H3 and
H4. Histone H2AX is a variant of histone H2A and
accounts for 10-15% of all variants. When DNA damage
occurs, serine 139 of histone H2AX in chromatins on
both sides of a damaged site is phosphorylated by two
enzymes: ataxia telangiectasia mutated (ATM) protein
kinase and by ATM and Rad3 related (ATR) protein kin-
ase [8,9]. Phosphorylated histone H2AX is called
γH2AX. Dot γH2AX, which is detectable using γH2AX-
specific antibody, is considered to correspond to specific
DNA damage. Therefore, DNA damage can be immuno-
cytochemically detected [10]. DNA damage in individual
cells has been detected employing a single-cell DNA gel
electrophoresis technique (comet assay), in which the
extent and length of the comet’s tail indicate the severity
of DNA damage. Recently, however, it has become ap-
parent that phosphorylation of histone H2AX, one of
the variants of the nucleosome core histone H2A, can
provide a sensitive and reliable marker of DNA damage.
More specifically, DNA damage, particularly that involv-
ing the formation of DNA double-strand breaks (DSBs),
induces phosphorylation of histone H2AX on Ser-139;
phosphorylated H2AX is defined as γH2AX. The phos-
phorylation takes place on H2AX molecules on both
sides of DSBs along a megabase length of DNA. Al-
though DSBs generated during DNA fragmentation in
the course of apoptosis also induce γH2AX, the degree
of γH2AX induction in apoptotic cells is much greater
than that in primary DSBs induced by antitumor drugs
or radiation. The presence of γH2AX in cells can be
detected immunocytochemically in the form of distinct
nuclear γH2AX immunofluorescent foci and each focus
is considered to correspond to a single DSB. This im-
munocytochemical approach has made it possible to
assay DNA damage and in situ repair of the chromatin
of individual cells. The immunocytochemical approach
is significantly more sensitive than the comet assay. The
use of multi-parameter flow cytometry in measurements
of γH2AX immunofluorescence allows DNA damage to
be correlated with cellular DNA content and, therefore,
the cell-cycle phase. Determination of the cell-cycle
phase targeted by the drug is of importance in elucidat-
ing the mechanism of antitumor drug activity.In the present study, we conducted flow cytometric bi-
variate analyses of γH2AX and DNA contents in two dif-
ferent cell lines of CCC treated with CDDP, CBDCA,
PTX or CPT-11 (SN-38), which have been used in the
aforementioned international clinical randomized trial
targeting CCC, and examined effects of these drugs with
regard to the induction of DNA damage, apoptosis and
cell-cycle progression vis-à-vis the cell-cycle phase.
Materials and methods
Cell culture
We used two CCC cell lines (OVISE and RMG-I) were
obtained from the Health Science Research Resources
Bank (Osaka, Japan). OVISE was established from a pa-
tient with metastatic disease after completion of six
cycles of platinum combination therapy, and was grown
in dishes (Becton Drive, Franklin Lakes, NJ, USA) in
RPMI1640 medium (Sigma Chemical Co., St Louis, MO,
USA) with 10% fetal bovine serum. RMG-I was estab-
lished from a chemotherapy-naïve patient with ascites,
and was reported to be primary platinum resistant
(Table 1) [11]. RMG-I was grown in dishes (Becton
Drive) in Ham F-12 medium supplemented with 10%
fetal bovine serum. The media for the two cell lines were
supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin (Meiji Seika Co., Ltd., Tokyo, Japan). All
cell lines were maintained at 37°C in a humidified at-
mosphere of 5% CO2 in air.
Drugs
CDDP, PTX and SN-38 (CPT-11) were dissolved in di-
methyl sulfoxide (DMSO, Sigma); the final concentration
of DMSO in the culture medium never exceeded 0.1%
(w/v). CBDCA was dissolved in phosphate-buffered sa-
line (PBS). The concentration of each agent was set to
correspond to the blood concentration at a standard
clinical dose (Table 2).
Immunohistochemistry
Both cells floating in the medium and the cells that
remained attached after trypsinization were collected and
fixed with 1% methanol-free formaldehyde (Polysciences
Inc., Warrington, PA, USA) in PBS at 0 °C for 15 minutes
and post-fixed with 80% ethanol for at least 2 hours at −20
°C. The fixed cells were washed twice in PBS and
Table 2 Minimum effective concentration (MEC)
Cmax MEC
PTX 10 μg/ml 50 ng/ml
CDDP 7 μg/ml 1 μg/ml
CBDCA 55 μg/ml 10 μg/ml
SN-38 30 μg/ml 1 ng/ml
Cmax; clinical maximum drug concentration.
Figure 1 Immunohistochemistry. Representative microscopic
images of OVISE cell line after exposure to 10 μg/ml CDDP for 24 h.
γH2AX foci in a nuclear are stained green and red, respectively. An
increase in green dots, indicating elevation of γH2AX, can be seen
after exposure to CDDP. Thus, DNA damage is visually recognizable
in each nucleus. Apoptotic bodies (insert) are distinguishable by the
entire cell being intensely positive for γH2AX.
Takatori et al. Journal of Ovarian Research 2012, 5:16 Page 3 of 9
http://www.ovarianresearch.com/content/5/1/16suspended in a 1% (w/v) solution of bovine serum albumin
(BSA) (Sigma) in PBS to suppress non-specific antibody
binding. The cells were then incubated in 100 μl of 1%
BSA containing 1:100 diluted anti-phosphohistone H2AX
(Ser-139) monoclonal antibody (Upstate, Lake Placid, NY,
USA) for 2 hours at room temperature, washed twice with
PBS and resuspended in 100 μl of 1:20 diluted fluorescein
isothiocyanate (FITC)-conjugated F(ab’)2 fragment of goat
anti-mouse immunoglobulin (Dako, Glostrup, Denmark)
for 30 minutes at room temperature in the dark. The cells
were then counterstained with 5 μg/ml propidium iodide
(PI) (Sigma) in the presence of 100 μl of RNaseA (Sigma)
for 30 minutes.
Fluorescence measurements by flow cytometry
The FITC (green) and PI (red) fluorescence of individual
cells in suspension induced by excitation with a 488-nm
argon ion laser was measured using a FACScan flow cyt-
ometer (Becton-Dickinson, San Jose, CA, USA). The green
and red fluorescence from each cell was separated and
quantified using standard optics and Cell Quest software
(Becton-Dickinson). Ten thousand cells were measured per
sample. All experiments were repeated at least three times.
After γH2AX and DNA staining, the DNA content
was represented on the x axis and the γH2AX content
on the y axis using flow cytometry. The γH2AX in each
cell cycle was determined, thereby allowing the relation-
ships between cell kinetics and DNA damage induced by




OVISE cells showed an increase in the number of distinct
green dots (γH2AX foci) after exposure to 10 μg/ml CDDP
for 24 h, which indicates that CDDP caused DNA damage
(Figure 1). Using folw cytometry, DNA damage was evident
from the increase in γH2AX. After 24-hour treatment with
CDDP, DNA damage in OVISE and RMG-I was seen grad-
ually in the S phase at concentrations of 100 ng/ml and
1 ng/ml (Figure 2A). In both cell lines, treatment with
100 ng/ml or more CDDP for 24 hours caused DNA dam-
age throughout the cell cycle. The cells with DNA damage
gradually underwent apoptosis, as was evident by the pres-
ence of cells with markedly elevated γH2AX and fractional(sub-G1) DNA contents. In OVISE, DNA damage in the S
and G2/M phases after treatment with 100 ng/ml CDDP
was seen for 24 and 72 hours, respectively (Figure 2B). Al-
though in RMG-I, 100 ng/ml CDDP caused DNA damage
in the S phase, in other phases of the cell cycle it was not
apparent even with longer treatment. In both cell lines, the
cells with damaged DNA underwent apoptosis. The num-
ber of cells in the G2/M phase in OVISE decreased grad-
ually indicating S-phase arrest. . On the other hand, in
RMG-I showed G1 and G2/M-phases arrest. RMG-I was
found to be less susceptible to DNA damage and subse-
quent apoptosis than OVISE.
CBDCA
DNA damage in the S phase was seen gradually after ex-
posure to CBDCA for 24 hours in OVISE and RMG-I
lines at 1 μg/ml and 10 μg/ml, respectively (Figure 3A).
Subsequently, the cells with damaged DNA underwent
apoptosis. Gradually both cell lines showed DNA damage
in the G2/M phase and underwent apoptosis. OVISE
showed S and G2/M- phases arrest, while RMG-I G2/M-
phase arrest (Figure 3B).
PTX
Exposure to 10 ng/ml or more PTX for 24 hours caused
apoptosis without primary DNA damage in both cell lines.
(Figure 4A). Although, further apoptotic effects were not
seen at doses exceeding 50 ng/ml. PTX induced both cell
lines G2/M-phase arrest, but some cells remained 120
hours after exposure without primary DNA damage
(Figure 4B).
Figure 2 Bivariate distributions (DNA content vs. γH2AX) of CCC cell lines, OVISE and RMG-I, treated with CDDP (Upper, OVISE; Lower,
RMG-I). The dotted lines indicate the upper level of γH2AX immunofluorescence for 95% of cells in the untreated (control) culture. Arrow heads
indicate elevation of γH2AX that means DNA damage. Arrows indicate apoptotic cell populations with marked increase in γH2AX and gradual
decrease in DNA. (A) Both cell lines treated with various concentrations of CDDP for 24 h. OVISE and RMG-1 cell lines exhibited DNA damage in
S-phase cells at minimum concentrations of 100 ng/ml and 1 μg/ml, respectively. Both cell lines were subjected to DNA damage concentration-
dependently at every cell cycle, and apoptosis was induced at concentrations of 5 μg/ml or higher. More cells in RMG-1 remained free of DNA
damage as compared to OVISE. (B) Both cell lines were treated with 100 ng/ml, the minimum concentration inducing DNA damage in either cell
line, for various reaction times. S-phase cells of OVISE showing DNA damage progressed to apoptosis after 48 h. In addition, S-phase arrest was
observed. DNA damage was induced in S-phase cells of RMG-I after 48 h. Cells with DNA damage progressed to apoptosis after 72 h.
Furthermore, cell-cycle arrest occurred in all cells.
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Figure 3 Bivariate distributions (DNA content vs. γH2AX) of OVISE and RMG-I cell lines, treated with CBDCA (Upper, OVISE; Lower,
RMG-I). The dotted lines indicate control. Arrow heads and arrows indicate DNA damage and apoptosis, respectively. (A) Both cell lines treated
with various concentrations of CBDCA for 24 h. DNA damage was observed in the S-phase cells at 1 μg/ml and 10 μg/ml concentrations in OVISE
and RMG-1, respectively. DNA damage was found in both cell lines at every cell cycle as the concentration increased, and apoptosis occurred at a
concentration of 50 μg/ml. More cells remained free of DNA damage in RMG-1 than in OVISE. (B) Both cell lines were treated with 1 μg/ml, the
minimum concentration inducing DNA damage in either cell line, for various reaction times. In OVISE, S-phase cells with DNA damage progressed
to apoptosis after 48 h. DNA damage was also found in G2/M-phase cells after 48 h, but most did not progress to apoptosis. S and G/2 M-phase
arrests were observed. DNA damage was found in S and G2/M-phase cells after 48 h in RMG-I. The S-phase cells with DNA damage progressed to
apoptosis 78 h later, but G2/M-phase cells showing DNA damage remained. S and G/2 M-phase arrests were observed.
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Figure 4 Bivariate distributions (DNA content vs. γH2AX) of OVISE and RMG-I cell lines, treated with PTX (Upper, OVISE; Lower, RMG-I).
The dotted lines and arrows indicate control and apoptosis, respectively. (A) Both cell lines treated with various concentrations of PTX for 24 h.
Both cell lines included cells that had progressed to apoptosis without direct DNA damage induced by a minimum concentration of 10 ng/ml.
No concentration-dependent differences were observed at concentrations of 50 ng/ml or higher. (B) Both cell lines were treated with 10 ng/ml,
the minimum concentration inducing DNA damage in either cell line, for various reaction times. G2/M-phase arrest occurred in both cell lines.
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After treatment with 0.5 ng/ml or more of SN-38 for 24
hours, both cell lines distinguished DNA damage in the
S phase. Nevertheless even 10 ng/ml which is nearly the
clinical maximum blood concentration did not causeapoptosis (Figure 5A). Apoptosis was seen barely 72
hours after exposure to 0.5 ng/ml SN-38 in a portion of
OVISE while in RMG-I after 96 hours (Figure 5B). How-
ever, the cells with significant DNA damage remained in
the S phase over 120 hours after exposure.
Figure 5 Bivariate distributions (DNA content vs. γH2AX) of OVISE and RMG-I cell lines, treated with SN-38 (Upper, OVISE; Lower, RMG-
I). The dotted lines indicate control. Arrow heads and arrows indicate DNA damage and apoptosis, respectively. (A) Both cell lines treated with
various concentrations of SN-38 for 24 h. Both cell lines exhibited DNA damage in S-phase cells at a minimum concentration of 0.5 ng/ml. (B)
Both cell lines were treated with 0.5 ng/ml, the minimum concentration inducing DNA damage in either cell line, for various reaction times. S-
phase cells with DNA damage started progressing to apoptosis after 72 and 96 h in OVISE and RMG-1, respectively. Both cell lines showed S-
phase arrest, and large numbers of cells with DNA damage were still present even after 120 h.
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After CDDP administration, DNA damage was observed
mainly in the S phase. It is reasonable to assume that
the DNA was structurally altered by CDDP, leading to
DNA replication fork arrest and ultimately resulting inapoptosis. This result was consistent with a known
pharmacological effect of CDDP [12]. In RMG-I, apop-
totic cells were minimally increased in the S phase,
moreover the cells showing arrest in the G1 and G2/M
phases without DNA damage were increased as
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present study support the clinical experience that RMG-
I is CDDP-resistant [11,13]. After CBDCA administra-
tion, DNA damage was seen in the S and G2/M phases
in both cell lines. OVISE contained a remarkable cell
population rescued from apoptosis and surviving with
DNA damage. On the other hand, most RMG-I cells
with DNA damage underwent apoptosis. These results
suggest that cell lines respond differently to platinum
agents, i.e., RMG-I was CDDP-resistant but responded
to CBDCA. PTX directly induced apoptosis in M-phase
cells but not via DNA damage, an observation consistent
with a known pharmacological effect of PTX, i.e. micro-
tubule inhibition [14]. PTX was confirmed to induce
apoptosis through a p53-independent pathway; it was,
therefore, expected to have an effect on CCC, in which
the p53 mutation is rare [15,16]. The mechanism under-
lying the antitumor effect of PTX is G2/M arrest. There-
fore, the combination with CBDCA, an agent inducing
DNA damage, in G2/M-phase arrested cells might be ef-
fective, at least theoretically. As shown in this study, it is
noteworthy that sensitivities to CDDP and CBDCA dif-
fered between the CCC cell lines. In practice, CCC is
less sensitive to CBDCA/PTX treatment [4,6,17], which
is the standard regimen for ovarian cancer. Since the ef-
fect of PTX was independent of both the concentration
and the response time, these results raise the possibility
that repeated administration of PTX at a low dose
increases the antitumor effect more than a single admin-
istration. These findings support the results of the
JGOG3016, i.e. that weekly CBDCA (AUC6)/PTX
(80 mg/m2, weekly × 3) is more effective than tri-weekly
CBDCA (AUC 6)/PTX (175 mg/m2) treatment [18].
On the other hand, after administration of SN-38,
DNA damage occurred in S-phase cells, followed by
apoptosis. This confirmed that SN-38 acts as a type I
topoisomerase inhibitor [19]. Furthermore, it appears
that SN-38 had an effect on the cell cycle because S-
phase arrest continued for more than 120 hours. It is,
therefore, possible that the improved administration
method for SN-38 increases its antitumor effect. Cells
rescued from apoptosis remained in S phase with DNA
damage; consequently, the efficacy of combining SN-38
with CDDP, which induces DNA damage mainly in S-
phase cells, was supported.
In conclusion, the present results suggest that an ef-
fective treatment for CCC with a slow growth rate and a
low ratio of S-phase cells would be a combination of
agents arresting the cell cycle, thereby causing accumu-
lation of cells in the S phase or the G2/M phase, and
agents specifically inducing DNA damage in S-phase
cells. The method used in this study allows immuno-
cytochemical detection of γH2AX, which indicates DNA
damage even at very low concentrations and has highsensitivity in comparison with the comet assay. Employ-
ing this method, we were able to analyze relationships
between anti-tumor effects and cell cycle perturbations.
Therefore, γH2AX detection is a promising method of
simply and rapidly identifying agents potentially effective
against CCC.
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